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Background: S-1 is an oral cytotoxic preparation that contains tegafur. Gamma-butyrolactone (GBL) is a 
metabolite of tegafur that is known to suppress vascular endothelial growth factor (VEGF)-mediated 
angiogenic activity. The aim of this study was to determine the change in Circulating Endothelial Cells 
(CEC) counts, GBL levels, and angiogenesis-related factors during S-1 administration in metastatic breast 
cancer (MBC) patients.  
Methods: Patients with HER2-negative MBC were eligible. S-1 was administered orally twice daily in a 
4-week-on/2-week-off cycle until disease progression or unacceptable toxicity occurred. Blood was 
collected on the following days: day 1, day 43, day 85 (before each cycle of S-1 administration), day 15, 
day57 (1 h after S-1 administration), and day29. The CellSearch® system was used to count the CECs. 
Gas chromatographic-mass spectrometric method was used to measure plasma GBL and 5-FU levels. 
Levels of VEGF were assayed by enzyme-linked immunosorbent assay.  
Results: A total of 18 patients were enrolled. The plasma GBL levels on day 15 and day 57 were 41.3 ± 
15.8 ng/mL and 41.0 ± 11.2 ng/mL, respectively. The CEC levels decreased on day 15, and significantly 
low levels were maintained until day 85 (P = 0.002 vs. day 1). The plasma VEGF levels significantly 
decreased on day15 (P = 0.012 vs. day 1) and had a tendency to decrease until day 57.  
Conclusions:  This exploratory study showed that GBL levels increased, VEGF levels decreased, and 




This exploratory study showed that GBL levels increased, VEGF levels decreased, and CEC levels were 
suppressed during S-1 administration. S-1 appears to have anti-angiogenic activity. 
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Metastatic breast cancer (MBC) is rarely curable, which increases the importance of 
maximizing the quality of life during treatment. Currently, mainstream chemotherapy for MBC is 
delivered at the maximum tolerable dose (MTD), usually given every few weeks. An alternative approach 
is metronomic chemotherapy, which is characterized by relatively low dosages and more frequent 
administration of the chemotherapeutic agent that typically results in fewer side effects and better quality 
of life 1.  
Two of the agents that meet the characteristics of metronomic chemotherapy are UFT and S-1. 
S-1 consists of tegafur (FT), 5-chloro-2,4-dihydroxypyridine and potassium oxonate at a molar ratio of 
1:0.4:1, respectively. UFT, an oral fluoropyrimidine that combines FT and uracil at a molar ratio of 1:4, 
was developed earlier than S-1 2. The chief component of both S-1 and UFT is FT, which is a prodrug of 
5-fluorouracil (5FU) 3. Patients with positive hormone receptor status treated with UFT showed longer 
relapse-free survival than those treated with CMF in clinical trials 4,5. The hormone receptor-positive and 
HER2-negative subpopulations of patients are not as responsive to treatment with anthracycline or taxane 
6,7. S-1 is also expected to be particularly effective in patients with positive hormone receptor status. 
Metronomic chemotherapy is considered to inhibit tumor growth by anti-angiogenic effect via 
direct targeting of dividing endothelial cells in the growing tumor vasculature and of circulating 
endothelial progenitors (CEPs) 8,9. MTD chemotherapy induced robust CEP mobilization and tumors 
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rapidly became resistant 1. Metronomic chemotherapy is sometimes effective at targeting tumors that are 
resistant to chemotherapy with MTD because the main targets of metronomic chemotherapy are the 
endothelial cells of the growing vasculature of the tumor 9,10. Administration of metronomic 
cyclophosphamide (CPA) is reported to maintain low levels of viable circulating endothelial cells (CECs) 
for a long period of time by avoiding mobilization of CEPs 1. FT is metabolized into 5FU, 
γ-butyrolactone (GBL), and γ-hydroxybutyric acid (GHB). GBL and GHB are tautomers under 
physiological conditions and are known to suppress tumor-mediated or VEGF-mediated angiogenic 
effects 11,12. In a mouse model of MBC, low doses of CPA and UFT resulted in remarkable prolongation 
of survival and decline in viable CEPs without myelosuppression 9. 
To optimize metronomic chemotherapy, development of reliable surrogate markers for 
anti-angiogenesis may be useful. Several studies have reported that changes in CEPs could act as a 
biomarker for monitoring therapeutic effect 1,13-17. The numbers of CEPs are higher in breast cancer 
patients with Stage III/IV than in patients with Stage I/II, and the numbers decline after chemotherapy 16. 
The maximum reduction in CEPs is strongly correlated with the anti-angiogenic effect 17. From these 
findings, the assumption arises that S-1 has anti-angiogenic effects that results in declining CEPs if S-1 is 
shown to have a similar anti-angiogenic effect as that of UFT 12,18. CECs are increased in cancer patients 
compared with non-diseased individuals and have been suggested as potential predictors of clinical 
response 1,14,15,19,20. The change in CEC counts differs for each chemotherapeutic agent. A CEC count 
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greater than 11/µL after 2 months of metronomic chemotherapy with oral 2.5 mg of methotrexate and 50 
mg of CPA administration was associated with significantly prolonged overall survival in MBC patients 20. 
Metronomic methotrexate and CPA administration lets CEC counts increase, but the change in CEC count 
for S-1 administration is unknown so far. The main purpose of this study was to explore corresponding 
levels of CECs in MBC patients during S-1 administration. Another purpose was to assess the change in 
GBL levels and angiogenesis-related factors: VEGF, monocyte chemo-attractant protein-1 (MCP-1), and 
thrombospondin-1 (TSP-1)21,22. Furthermore, the changes in the circulating tumor cells (CTCs), M30 and 
M65 were also determined.  
 
Patients and methods 
Patients 
Patients aged 20 years and older with histologically confirmed invasive breast cancer and the 
following were eligible: MBC that was not necessarily measurable according to the Response Evaluation 
Criteria in Solid Tumors; Eastern Cooperative Oncology Group performance status of 0—2; negative 
HER2 status; adequate bone marrow and organ functions (WBCs ≥3000/mm3 or neutrocytes ≥1500/mm3, 
platelets ≥ 10×104/mm3, hemoglobin 9.0 g/dL, AST•ALT ≤ 2.5 × the upper limit of normal range adopted 
by the institute, total bilirubin ≤ 1.5 mg/dL, creatinine ≤ 1.2 mg/dL, creatinine clearance ≥ 60 mL/min). 
Patients who had already received S-1 within the previous 12 months were excluded. Patients were also 
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excluded if they had an active concomitant malignancy, a history of allergy to fluorinated pyrimidine, 
interstitial pneumonia, or pulmonary fibrosis. The use of fluorinated pyrimidine, steroids, or flucytosine 
was not allowed. Pregnant or lactating women were excluded. Written informed consent was required 
from all participants.  
 
Study design 
The patients received S-1 (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) orally for 28 
consecutive days, followed by a 14-day rest period (Fig. 1a). Cycles were repeated every 42 days until 
disease progression or unacceptable toxicity occurred. The standard dose of S-1 was determined on the 
basis of body surface area (BSA) as follows: for BSA < 1.25 m2, 80 mg/body/day; for 1.25 m2 ≤ BSA < 
1.5 m2, 100 mg/body/day; and for 1.5 m2 ≤ BSA, 120 mg/body/day. The standard dose was given daily in 
two divided doses. One point of blood was collected on each of the following days: day 1 (before the 1st 
cycle of S-1 administration), day 15 (1 h after S-1 administration), day 29, day 43 (before the 2nd cycle of 
S-1 administration), day 57 (1 h after S-1 administration), and day 85 (before the 3rd cycle of S-1 
administration). This explorative trial was approved by the Kyoto University Graduate School and 
Faculty of Medicine Ethics Committee and registered with the University Hospital Medical Information 





On days 1, 15, 29, 43, and 85, 20-mL aliquots of blood were collected into two CellSave 
Preservative Tubes (Veridex LLC, Co., Ltd, NJ, USA) containing a cell preservative. Blood samples for 
CECs and CTCs were kept at room temperature and centrifuged at 800 g for 10 minutes within 24 h of 
sampling. The CellSearch® System (Veridex LLC, Co., Ltd) was used to measure the CECs, 
CD34+CECs, and CTCs. The CellSearch® System consists of CellSave Preservative Tubes, the 
CellTracks® Autoprep® System (a fully automated sample preparation system), the CellSearch® 
Circulating Endothelial Cell Kit, the CellSearch® Circulating Tumor Cell Kit, and the CellTracks 
Analyzer II® (a semi-automated fluorescence microscope). The CECs were identified as 
4,6-diamino-2-phenylindole (DAPI)+, CD45—, CD146+, and CD105+ cells. CECs were additionally 
stained with anti-CD34 antibody (Clone AC136; Miltenyi Biotec, Germany), and CD34 expression was 
evaluated on an extra channel of the CellSearch system. Therefore, the CD34+ CECs were identified as 
DAPI+, CD45—, CD146+, CD105+, and CD34+ cells. The CTCs were defined as 
DAPI+CD45—EpCAM+CK8+CK18+CK19+ cells. All evaluations were performed by the same 
operator. 
For enzyme-linked immunosorbent assay (ELISA) and 5FU and GBL measurements, 15-mL 
aliquots of heparinized peripheral venous blood were collected on days 1, 15, 43, and 57, kept at room 
temperature for less than 30 minutes, and centrifuged at 3000 r.p.m. at 4°C for 15 minutes. Plasma 
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samples were stored at —80°C until measurements of 5FU, GBL, and by ELISA. The plasma levels of 
GBL and 5FU were determined by a gas chromatographic-mass spectrometric method (FALCO 
Biosystems Ltd., Kyoto, Japan) 23.  Plasma levels of VEGF (Quantikine®, Human VEGF Immunoassay; 
R&D Systems, Inc., Minneapolis, MN, USA), MCP-1 (Quantikine®, Human MCP-1 Immunoassay; 
R&D Systems, Inc., Minneapolis, MN, USA), TSP-1 (Quantikine®, Human TSP-1 Immunoassay; R&D 
Systems, Inc., Minneapolis, MN, USA), M30 (M30® ELISA; PEVIVA AB, Bromma, Sweden), and M65 
(M65® ELISA; PEVIVA AB, Bromma, Sweden) were measured by ELISA according to the 
manufacturer’s instructions. M30 and M65 ELISAs detect different circulating forms of the protein 
cytokeratin 18 24,25. M30 recognizes a fragment of cytokeratin 18 cleaved during apoptosis while M65 
recognizes both cleaved and uncleaved forms of cytokeratin 1826. 
 
Toxicity and clinical evaluations 
Toxicities were evaluated according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (version 3.0) throughout the S-1 treatment. The clinical effect was assessed as 
progressive disease (PD) or non-PD. 
 
Statistical analysis 
To evaluate differences in the distribution of the markers, statistical significance was assessed 
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by the Wilcoxon signed-rank test. JMP version 9 software (SAS Institute Inc., Cary, NC, USA) was used 
for statistical analysis. 
 
Results 
Patient characteristics and clinical course 
A total of 18 female patients with histologically-proven invasive breast carcinoma and 
metastatic or relapsed breast cancer were enrolled in this study. The patients’ characteristics are described 
in Table 1. The clinical course and toxicities are described in Table 2. Endocrine therapy was administered 
concurrently to 15 patients (83.3%). Six patients (33.3%) aborted S-1 administration because of side 
effects or progressive disease before day 85. Four patients (22.2%) had progressive disease (PD) by day 
85. Toxicities greater than or equal to grade 2 were anemia (16.7%), leukopenia (16.7%), neutropenia 
(16.7%), rash (16.7%), malaise (11.1%), pigmentation (5.6%), and diarrhea (5.6%). Nine patients (50%) 
had no toxicity greater than grade 2. 
 
Blood levels of 5-FU and GBL 
Before the administration of S-1 on days 1 and 43 (before the 2nd cycle of S-1 administration), 
5-FU was not detected in the blood of any patients. The mean 5-FU concentrations are shown in Table 3. 
The plasma GBL levels are shown in Fig. 1b and Table 3. The individual plasma 5-FU and GBL levels 
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significantly elevated at day 15 compared to day 1 (P = 0.008). The levels were also elevated on day 57 
compared with those on day 1 (P = 0.008) and day 43 (P = 0.008). The plasma GBL level on day 43 was 
significantly decreased from that on day 15 (P = 0.016). Plasma GBL can be detected before S-1 
administration because it exists endogenously in human plasma.  
 
Change in CECs and CD34 + CECs during S-1 treatment 
The mean CEC and CD34+ CEC counts had a tendency to decrease notably from day 1 to day 
15 and were suppressed until day 85. The reductions in CEC counts were significant on day 29 (P = 0.010 
vs. day1) and day 85 (P = 0.002 vs. day 1) (Fig. 2a and Table 3). The reductions in CD34+ CEC counts 
were significant on day 29 (P = 0.017 vs. day1) and day 85 (P = 0.003 vs. day 1) (Fig. 2b and Table 3). 
 
Angiogenesis-related proteins 
The mean VEGF level significantly decreased on day 15 (P = 0.012) (Fig. 2c). The plasma 
MCP-1 level significantly increased from day 1 to day 15 (P = 0.002) and from day 43 to day 57 (P = 
0.002), and there was a statistically significant decrease from day 15 to day 43 (P = 0.005). The mean 
TSP-1 level on day 57 significantly decreased from day 1 (P = 0.016) (Table 3). 
 
Change in the CTCs, M30, and M65 
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The mean CTC counts had a tendency to decrease from day 1 until day 29 and then increase 
from day 29 to day 85, although there was large individual variation. The mean CTC counts significantly 
increased on day 43 from day 29 level (P = 0.031). The mean levels of M30 and M65 tended to converge 
from day 1 until day 57 (Table 3). No statistical correlation was observed between clinical effects and any 
measured biomarkers except M30 change in value from day1 to day 15 (Table 4). M30 of the patients 
with non-PD increased from day 1 to day 15, while that of the patients with PD decreased from day 1 to 
day 15 (P = 0.030). 
 
Discussion 
We showed that CEC counts after S-1 administration notably decreased on day 15 and were 
significantly suppressed until day 85 in MBC patients. The plasma levels of 5FU and GBL significantly 
increased after S-1 administration. The plasma VEGF levels significantly decreased from day 1 to day 15. 
One of the limitations of this study was that blood samples obtained for analysis were taken 1 h 
after S-1 administration although the level of 5FU at 1 h after administration cannot be used as a 
representative level of systemic exposure. Endogenous GBL is observed in not only cancer patients but 
also healthy volunteers without administration of S-1, and no differences in the endogenous concentration 
of GBL were found between them 27. Currently, the plasma pharmacokinetics of GBL after S-1 
administration are unknown, although Emi et al. showed that the values of Tmax for GBL after UFT 
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administration were 1.2+/-0.6 h 27. Sampling for other biomarkers, including CEC counts or VEGF, are 
also considered to be appropriate 1 h after S-1 administration. On the basis of these factors together with a 
feasible schedule in an outpatient setting, we decided to collect blood 1 h after S-1 administration.  
Of 18 patients, 15 (83.3%) had combined treatments with hormone therapy or zoledronic acid, and 
12 patients (72.2%) secured S-1 administration without unacceptable toxicity or PD. Considering that 14 
patients (77.8%) had non-PD, S-1 is suitable for MBC patients. No statistical correlation between clinical 
effects and any measured biomarkers except M30 change in value from day 1 to day 15 was observed. As 
reported before 28,29, M30 can be used to assess tumor apoptosis. However, the number of patients was 
small because the primary endpoint of this study was to explore corresponding levels of CECs and the 
change in angiogenesis-related factors. Additionally, 3 out of 4 patients with PD discontinued S-1 before 
day 85. These results are preliminary, and the correlation between clinical effects and biomarkers remains 
to be elucidated in the future. 
VEGF is a potent angiogenic factor that is known to promote the mobilization of bone 
marrow-derived CEPs, which subsequently differentiate into mature CECs 30. A previous study of in vitro 
tube formation assay showed that GBL suppressed VEGF-mediated angiogenesis and that the IC50 of the 
anti-angiogenic effect was 25.8 ng/mL 11. Nagai et al. also reported that UFT and its metabolite GBL 
inhibited angiogenesis induced by VEGF in cervical cancer 18. In our present study, the mean GBL levels 
were 41.3 ± 15.8 and 41.0 ± 11.2 mg/mL at 1 h after S-1 administration on days 15 and 57, respectively, 
14 
 
which exceeded the IC50 of the anti-angiogenic effect 
11. From this result and that VEGF levels 
significantly decreased from day 1 to day 15, CEPs appear to be suppressed via VEGF inhibition during 
S-1 administration in the same manner as caused by UFT. 
Thus, S-1 should have not only a well-known cytotoxic effect but also an anti-angiogenic effect. 
More effective strategies may be developed for treatment of MBC; for example, S-1 is supposed to be 
more effective for tumors with abundant neovascularization. Approved angiogenesis inhibitors are 
suggested to have a strong angiogenic effect soon after discontinuation. When a patient needs to 
discontinue an angiogenesis inhibitor because of side effects, S-1 may have the potential to inhibit this 
reinduction. S-1 demonstrates marked benefits to MBC patients, considering approved anti-angiogenic 
drugs that are recommended for use with chemotherapeutic agents. Regarding the surrogate marker, the 
reduced CEC counts on day 15 suggest that the anti-angiogenic effect continues until day 85. 
CECs are composed of two distinct populations: vascular-derived CECs and bone 
marrow-derived CEPs. The former is considered to be mature CECs and caused by the damaged 
endothelium of the vasculature and the latter is regarded to be CEPs that contribute to neovascularization. 
Both have an important role in neovascularization and tumor growth, but there is no standard way to 
evaluate CEC counts and distinguish between them at present 31. We used the CellSearch® System to 
detect CECs, because of the automated nature of the CellTracks Analyzer II®, which reduces 
measurement deviations between different institutes. Although CD34 is expressed in not only endothelial 
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progenitor cells but also in some mature endothelial cells, it has been widely used to identify progenitor 
cells with clonogenic potential 19. We used CD34-positive CECs as populations similar to CEPs.  
In summary, plasma GBL levels were significantly elevated, and CEC counts were suppressed 
possibly via VEGF inhibition during S-1 administration. S-1 appeared to have anti-angiogenic activity, 
but the correlation between clinical effect and biomarkers including CEC counts was not observed in this 
exploratory study. Further studies are warranted to investigate the association between CEC dynamism 
and clinical outcomes in other situations, such as neoadjuvant or adjuvant settings. 
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Figure legends 
Fig. 1a: Scheme of S-1 administration and blood collection. The patients received S-1 for 28 days 
followed by a 14-day rest in one cycle. 
 
Fig. 1b: Plasma GBL levels on days 1, 15, 43, and 57. The plasma GBL levels significantly increased on 
the 14th day from the first day in each cycle. Data are shown as mean ± SD. *P < 0.05. 
 
Fig. 2: Changes in CEC (a) and CD34+ CEC (b) counts from day1 through day85. Changes in plasma 
VEGF levels from day 1 to day 57 (c). Data are shown as mean ± SD. *P < 0.05. 
 
Table 1: Baseline characteristics of the patients (n = 18). 
 
Table 2: Clinical evaluations and toxicities of the patients (n = 18) 
 
Table 3: Plasma biomarker levels from day 1 through day 85. Measurement values are shown as mean ± 




Table 4: Biomarker changes in value from day 1 to day 15 by the patients with non-PD and PD. Values 
are indicated as mean ± SD. *P < 0.05.  
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Table 1 
Characteristic No. of patients %





 Premenopausal 4 22.2%
 Postmenopausal 14 77.8%
Metastatic sites
 Bone 12 66.7%
 Lung/Pleura 9 50.0%
 Lymph nodes 8 44.4%
 Liver 4 22.2%
 Breast (StageIV) 3 16.7%
 Brain 2 11.1%
 Pericardium 1 5.6%




Tumor hormone receptor status
 HR+ 16 88.9%
 HR- 2 11.1%
Prior therapy for metastatic disease
 No 1 5.6%
 Endocrine therapy 11 61.1%














toxicity (more than grade2)
1 positive TAM+LHRH analog, ZA day15 non-PD leukopenia (grade3), neutropenia (grade3), rash(grade2)
2 positive LET, ZA day85 non-PD leukopenia (grade3), neutropenia (grade2)
3 positive EXE day29 non-PD rush(grade2)
4 positive LET, ZA day85 non-PD leukopenia (grade2), neutropenia (grade2), anemia (grade2)
5 positive EXE day29 PD none
6 positive EXE+LHRH analog day85 non-PD none
7 positive hd-TOR, ZA day85 non-PD none
8 positive hd-TOR day29 PD malaise (grade2), pigmentation(grade2), rash (grade2)
9 positive ZA day85 non-PD anemia (grade2)
10 positive LET+LHRH analog, ZA day22 non-PD diarrhea (grade2)
11 positive LET, ZA day85 non-PD none
12 positive LET day85 non-PD none
13 positive EXE day85 non-PD none
14 negative none day85 PD anemia (grade2)
15 negative none day85 non-PD none
16 positive ANA day85 PD none
17 positive none day43 non-PD malaise (grade2)
18 positive LET day85 non-PD none
Table 3 
day1 day15 day29 day43 day57 day85
mean ± SD mean ± SD P mean ± SD P mean ± SD P mean ± SD P mean ± SD P
5FU (ng/mL) 0 71.9 ± 48.1 0.001*  vs. day1 0 1.000 vs. day1 86.3 ± 46.2 0.001* vs.day1
GBL (ng/mL) 20.5 ± 6.5 41.3 ± 15.8 0.008* vs. day1 27.3 ± 8.9 0.109 vs. day1 41.0 ± 11.2 0.008* vs.day1
CEC (cells/4mL) 56.5 ± 31.5 35.7 ± 26.7 0.082 vs. day1 29.3 ± 17.2 0.010* vs. day1 34.3 ± 16.4 0.064 vs. day1 24.8 ± 12.6 0.002* vs. day1
CD34+ CEC (cells/4mL) 41.1 ± 24.6 26.3 ± 21.6 0.151 vs. day1 19.9 ± 10.7 0.017* vs. day1 26.4 ± 12.5 0.129 vs. day1 18.3 ± 9.3 0.003* vs. day1
VEGF (pg/mL) 73.6 ± 56.5 43.8 ± 21.9 0.012* vs. day1 47.3 ± 29.6 0.129 vs. day1 39.7 ± 15.3 0.424 vs.day1
MCP-1 (pg/mL) 202.7 ± 64.6 276.1 ± 107.5 0.002* vs. day1 175.1 ± 46.5 0.898 vs. day1 232.6 ± 64.0 0.206 vs. day1
TSP-1 (ng/mL) 1.49 ± 0.74 1.01 ± 0.41 0.129 vs. day1 1.09 ± 0.62 0.064 vs. day1 1.06 ± 0.48 0.016* vs. day1
CTC (cells/7.5mL) 13.3 ± 35.1 3.0 ± 3.8 0.681 vs. day1 1.5 ± 2.4 0.313 vs. day1 4.2 ± 7.7 1.000 vs. day1 5.7 ± 14.2 0.914 vs. day1
M30 (U/L) 170.3 ± 63.3 153.6 ± 54.9 0.970 vs. day1 140.5 ± 41.9 0.569 vs. day1 136.2 ± 32.6 0.733 vs. day1
M65 (U/L) 626.7 ± 374.2 455.2 ± 264.7 0.233 vs. day1 426.4 ± 161.8 0.233 vs. day1 413.7 ± 174.2 0.077 vs. day1
Table 4 
Patients with non-PD Patients with PD
mean ± SD mean ± SD P
5FU (ng/mL) 71.9 ± 52.8 55.7 ± 40.2 0.856
GBL (ng/mL) 21.8 ± 13.7 20.9 ± 11.3 0.893
CEC (cells/4mL) -19.3 ± 33.9 -38.0 ± 28.7 0.281
CD34+ CEC (cells/4mL) -17.9 ± 27.7 -14.0 ± 17.5 1.000
VEGF (pg/mL) -21.9 ± 37.3 -57.6 ± 54.4 0.152
MCP-1 (pg/mL) 56.5 ± 43.7 132.9 ± 160.7 0.339
TSP-1 (ng/mL) -0.398 ± 0.614 -0.285 ± 0.784 0.710
CTC (cells/7.5mL) -1.3 ± 6.2 -1.0 ± 5.4 0.646
M30 (U/L) 33.3 ± 36.2 -24.5 ± 62.4 0.030*
M65 (U/L) -216.7 ± 306.9 -13.72 ± 113.5 0.265
Change in value from day 1 to day 15
